ScinoPharm Taiwan Ltd
TWSE:1789
ScinoPharm Taiwan Ltd
Deferred Income Tax
ScinoPharm Taiwan Ltd
Deferred Income Tax Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Deferred Income Tax | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Deferred Income Tax
NT$1.3m
|
CAGR 3-Years
55%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-8%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Deferred Income Tax
NT$468m
|
CAGR 3-Years
13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
12%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Deferred Income Tax
NT$21m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Deferred Income Tax
NT$104.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
68%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Deferred Income Tax
NT$1.1B
|
CAGR 3-Years
53%
|
CAGR 5-Years
45%
|
CAGR 10-Years
10%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Deferred Income Tax
NT$85.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
ScinoPharm Taiwan Ltd
Glance View
ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
See Also
What is ScinoPharm Taiwan Ltd's Deferred Income Tax?
Deferred Income Tax
1.3m
TWD
Based on the financial report for Dec 31, 2024, ScinoPharm Taiwan Ltd's Deferred Income Tax amounts to 1.3m TWD.
What is ScinoPharm Taiwan Ltd's Deferred Income Tax growth rate?
Deferred Income Tax CAGR 10Y
-8%
Over the last year, the Deferred Income Tax growth was -21%. The average annual Deferred Income Tax growth rates for ScinoPharm Taiwan Ltd have been 55% over the past three years , 17% over the past five years , and -8% over the past ten years .
You don't have any saved screeners yet